RELAPSING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Oral MS pill shows promise in reducing brain damage in trial
Disease control CompletedThis study tested different doses of an oral medication called SAR442168 to see how well it reduces new areas of inflammation (lesions) in the brain for people with relapsing multiple sclerosis (RMS). The 130 participants took the drug or a placebo for 16 weeks, and researchers u…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Five-Year checkup on promising MS pill shows lasting effects
Disease control CompletedThis study followed 125 people with relapsing multiple sclerosis (MS) for about five years to check the long-term safety and effectiveness of the oral drug SAR442168. The goal was to see if the drug continued to control the disease over time by reducing new brain lesions and rela…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New hope for MS patients when standard drugs stop working
Disease control CompletedThis study tested whether switching to the drug ofatumumab could better control multiple sclerosis in patients whose current treatments were no longer working effectively. It followed 562 adults with relapsing MS for 96 weeks after they switched from specific older medications. T…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Home-Injected MS drug shows promise in chinese patients
Disease control CompletedThis study tested how well and how safe the drug ofatumumab was for adults in China with relapsing multiple sclerosis (RMS). All 99 participants received the drug as a monthly injection they could give themselves at home after initial clinic visits. Researchers tracked how often …
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists track MS Drug's impact inside the brain
Disease control CompletedThis study aimed to understand how the approved MS drug ofatumumab affects specific immune cells in the brain called microglia. Researchers followed 10 adults with relapsing MS for 9 months after they started the drug. They used advanced brain scans and blood tests to see if chan…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
MS patients successfully switch from hospital IV treatments to home injections
Disease control CompletedThis study tested whether people with relapsing multiple sclerosis could safely switch from receiving intravenous (IV) antibody treatments every 6 months to monthly self-injections of ofatumumab. The research followed 111 participants for 12 months to see if the new treatment mai…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Researchers track Real-World MS treatment use and patient experience
Knowledge-focused CompletedThis completed study looked at how people in Australia with relapsing multiple sclerosis (MS) used a treatment called Kesimpta (ofatumumab) in their daily lives. It tracked if patients took their doses on time and explored how the treatment affected their fatigue, work productivi…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 17, 2026 12:55 UTC